Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK) had its price objective lowered by equities research analysts at HC Wainwright from $30.00 to $3.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 60.43% from the company’s current price.

A number of other research firms also recently weighed in on OTLK. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. BTIG Research dropped their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, November 29th. Finally, Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday, January 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Outlook Therapeutics has an average rating of “Moderate Buy” and an average price target of $12.00.

Outlook Therapeutics Stock Performance

NASDAQ OTLK opened at $1.87 on Tuesday. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $12.85. The stock has a market capitalization of $59.80 million, a P/E ratio of -0.21 and a beta of 0.58. The stock has a fifty day moving average of $1.88 and a 200-day moving average of $4.41.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, February 14th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). Equities research analysts forecast that Outlook Therapeutics will post -2.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Outlook Therapeutics

Several large investors have recently bought and sold shares of OTLK. Jane Street Group LLC boosted its position in shares of Outlook Therapeutics by 133.9% during the fourth quarter. Jane Street Group LLC now owns 26,218 shares of the company’s stock worth $50,000 after purchasing an additional 15,008 shares in the last quarter. Scotia Capital Inc. raised its stake in Outlook Therapeutics by 124.4% during the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock worth $140,000 after buying an additional 41,023 shares during the period. Renaissance Technologies LLC bought a new position in Outlook Therapeutics during the fourth quarter worth about $246,000. Russell Investments Group Ltd. grew its stake in Outlook Therapeutics by 34,936.7% in the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock valued at $32,000 after acquiring an additional 17,119 shares during the period. Finally, Commonwealth Equity Services LLC bought a new stake in shares of Outlook Therapeutics in the fourth quarter worth about $48,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.